Month: September 2026

8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Rathbones Group Plc
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Eleco Plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	21/09/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?         If it is a cash offer or possible cash offer, state “N/A”	No

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	1p Ordinary Shares
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:	1,157,410	1.37%
(2)   Cash-settled derivatives:
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	1,157,410	1.37%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit
1p Ordinary Shares	Sale	210	229.36p

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
1p Ordinary Shares

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

No

Date of disclosure:	22/09/2026
Contact name:	Lydia Cotterill – Compliance Department
Telephone number:	0151 237 1176

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.

HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) — Orion Group Holdings, Inc. (NYSE: ORN) (the “Company” or “Orion”), a leading specialty construction company, today announced that management will participate in the 25th Annual D.A. Davidson Diversified Industrials & Services Conference on September 24 in Nashville, TN.

About Orion Group Holdings

Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental United States, Alaska, Hawaii, Canada and the Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design and specialty services. Its concrete segment provides turnkey concrete construction services including place and finish, site prep, layout, forming, and rebar placement for large commercial, structural and other associated business areas. The Company is headquartered in Houston, Texas. The Company’s website is located at: https://www.oriongroupholdingsinc.com.

Contact:

Margaret Boyce
346-278-3762
mboyce@orn.net

Source: Orion Group Holdings, Inc.

Company expects to achieve annualized Adjusted EBITDA-positive operations during 2027.

SEATTLE, Sept. 22, 2026 (GLOBE NEWSWIRE) — Roundtable (Nasdaq: RTB), an AI/DeFi-powered Enterprise Media Operating System, announces its 2027 operating forecast in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.

The Company forecasts $102 million in 2027 revenue and an Adjusted EBITDA-positive operations, based on current business and pipeline, and pro forma for the recently announced Paradium.AI partnership. Because the Company’s operating costs are largely fixed, significant operating leverage results as revenue scales past profitability.

2027 operating forecast (in $ millions)

		Q1 2027				FY 2027
Enterprise Media Customers			64				104
Monthly unique users (millions)			83.4				99.8
Revenue (million)		$	19.8			$	102.1
Cost of Sales		$	11.8			$	60.1
Gross profit		$	8.0			$	42.0
Gross margin			40	%			41	%
Operating expenses		$	7.0			$	28.8
Adjusted EBITDA		$	0.9			$	13.2

*Adjusted EBITDA is a non-GAAP financial measure intended to reflect steady-state operations and excludes certain non-cash, transaction, transition and one-time costs, including PAAI transaction and integration expenses, reimbursed severance and staff wind-down costs, stock-based compensation, licensing and vendor transition costs, depreciation and amortization, interest, capital expenditures and professional fees. A reconciliation to net income (loss), the most directly comparable GAAP measure, is not available without unreasonable effort due to the variability, complexity and limited visibility of these items, including the accounting treatment of the Paradium.AI transaction, which could materially affect GAAP results. The forecast requires successful closure of PAAI transaction, which requires financing. See the accompanying press release for the full non-GAAP disclosure.

The PAAI partnership brings sufficient scale and market-based pricing to RTB’s market leading capabilities – which benefit all RTB customers. Our business model eliminates customers’ SaaS operational costs, and grows traffic and engagement, enabling media customers to focus their resources on creating content and engaging audiences.

Roundtable provides a unified DeFi/AI platform to media companies, which typically rely on fragmented third-party systems. RTB’s platform integrates publishing, syndication, monetization, real-time payments, security, and AI protection against fraudulent traffic and other threats.

Background

After launching its platform in June 2026 at The Cannes Lions International Festival of Creativity, Roundtable began to onboard enterprise media customers in the third quarter of 2026. 2027 will be the first full year of at-scale platform operations, and settled in partnership with Coinbase.

2027 Strategy

Roundtable is initially focusing on onboarding customers in the sports, finance, technology and news sectors, the initial verticals of what the Company believes will be a 20-vertical premium information marketplace. Developing business into verticals provides scale for verticalized marketers and thus higher yield per inventory unit.

About Roundtable (RTB Digital, Inc.)

Roundtable (NASDAQ: RTB) is an AI/DeFi-powered Enterprise Media Operating System, integrating distribution, publishing, monetization, community, syndication and DeFi payment operations, powering professional and major media brands. The Web3 platform was developed over years by digital pioneers and co-founders, Eyal Hertzog and James Heckman.

For more information, visit rtb.io.

Cautionary Note Regarding Forward-Looking Statements

This press release includes information that constitutes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on the Company’s current beliefs, assumptions and expectations regarding future events, which in turn are based on information currently available to the Company. Such forward-looking statements include statements that are characterized by future or conditional words such as “may,” “will,” “expect,” “intend,” “anticipate,” “believe,” “forecast,” “estimate,” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Such forward-looking statements include statements regarding the accretive transactions undertaken in 2026 and future operations and revenues of the Company. By their nature, forward-looking statements address matters that are subject to risks and uncertainties. A variety of factors could cause actual events and results to differ materially from those expressed in or contemplated by the forward-looking statements, such as the Company being able to maintain its listing on Nasdaq for the common stock, having sufficient capital for its acquisitions, operations and business integration and expansion, and developing its business and capturing users for its services. Annualized and longer period revenue and business estimates are subject to the effect of macroeconomic events, industry changes, competitive forces, client development and retention, capital availability, and many other operational factors; therefore, any financial forecasts offered by the Company must take into account the fact that the underlying assumptions may not bear out or may significantly change over time and projected results may substantively increase or decrease. Other risk factors affecting the Company are discussed in detail in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable laws.

Investor Relations Contact: ir@roundtable.io
Public Relations Contact: pr@roundtable.io

39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients

Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partnership strategy for PDS0101

PRINCETON, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication of results from a Phase 2 trial evaluating PDS0101, its HPV16-targeted immunotherapy, in combination with pembrolizumab in the September 17, 2026, issue of JAMA Oncology, a peer reviewed journal of the American Medical Association. The data were published in an article titled “VERSATILE-002 – A Phase 2 Study of PDS0101 HPV16-targeted T Cell Immunotherapy and Pembrolizumab Combination in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Nonrandomized Clinical Trial.”

Key findings

• 62.3% of the ICI-naïve participants in the mITT cohort (n = 53) had low CPS of 1-19, and 37.7% had high CPS ≥ 20. In the overall CPS ≥ 1 population, the mOS was 39.3 months (95% CI, 23.9 to NE); The best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months ¹.

• Objective response rate (ORR) for CPS ≥ 1 was 36% of which 5/53 were complete responders by investigator review and 34% of which 6/53 were complete responders by central review.

• The published ORR for the overall population with CPS ≥ 1 when treated with standard of care pembrolizumab is 19%².

• The treatment was well-tolerated with 13.8% Grade ≥3 treatment-related adverse events (TRAEs), 1 Grade 4 event one year after PDS0101 therapy, and no Grade 5 TRAEs.

• The published safety profile for the overall population with CPS ≥ 1 when treated with standard of care pembrolizumab reports 17% Grade ≥ 3 TRAEs².

VERSATILE-002 was an open-label, non-randomized phase 2 trial performed at twenty-six oncology centers across the US, UK and Ireland. Eighty-eight patients with histologically confirmed R/M HPV16-positive diseases were enrolled in the study; 87 received treatment and comprised the safety population; 75 were in the modified Intention-to-Treat (mITT) population used for efficacy analyses: 53 ICI-naïve with PD-L1 CPS ≥1, 22 ICI-resistant (Mean age = 64.5 years, 94.7% male, 92.0% White).  

The trial was led by Dr. Jared Weiss, MD, of the Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, and was performed to determine the efficacy and safety of PDS0101, in combination with pembrolizumab in participants with HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), with separate evaluation of immune checkpoint inhibitor (ICI)-naïve and -resistant cohorts.

“We’re very pleased with the publication of the Phase 2 clinical results of the VERSATILE-002 clinical trial in a leading peer reviewed oncology journal,” said Dr. Kirk Shepard, M.D., Chief Medical Officer of PDS Biotech. “These results support the durable clinical effect of PDS0101, consistent with promising survival outcomes reported in two other recently published studies, the IMMUNOCERV study, and the NCI-led study in HPV16-positive recurrent and/or metastatic cancers. We believe PDS0101 has the potential to bring new hope to the rapidly growing population of HPV16-positive head and neck cancer patients.”

The Company recently announced the initial closing of a PIPE financing of up to $22.3 million led by Nant Capital, alongside an agreement granting NantWorks, LLC, an affiliate of Nant Capital, a one-year exclusive right to negotiate an exclusive license to PDS0101.

*No head-to-head trials have been performed.
¹Licitra L et al, J Clin Oncol; 2026 Apr 20;44(12):1098-1107.doi: 10.1200/JCO-25-00570. Epub 2026 Mar 12
²Harrington, KJ et al. J Clin Oncol. 2022;41:790-802. https://doi.org/10.1200/JCO.21.02508.

About PDS Biotechnology

PDS Biotechnology is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer. PDS Biotechnology owns the Versamune® cancer vaccine platform, including PDS0101, which has been evaluated in HPV16-positive cancers. The Company intends to pursue strategic partnerships or other externally funded opportunities for the Phase 3 development of PDS0101.

The Company’s lead development program, PDS0301 (also referred to as PDS01ADC & NHS-IL12), is an investigational tumor-targeted interleukin-12 (IL-12) immunocytokine designed to deliver IL-12 preferentially to the tumor microenvironment, with the goal of enhancing anti-tumor immune activity while limiting systemic exposure. PDS0301 has been clinically evaluated across multiple solid tumors, including metastatic colorectal cancer and prostate cancer. The Company is focused on advancing PDS0301 in indications where its tumor-targeted mechanism may help address and overcome mechanisms of resistance to immunotherapy.

For more information, please visit www.pdsbiotech.com

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to conduct clinical trials for PDS0301, PDS0101 (Versamune^® HPV), PDS0103 (Versamune^® MUC1) and other Versamune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0301, PDS0101 (Versamune^® HPV), PDS0103 (Versamune^® MUC1) and other Versamune^® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s or its partners’ ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding response rates, the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; compliance with the rules and regulations of Nasdaq; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.  
Versamune^® is a registered trademark of PDS Biotechnology Corporation.

Investor Contact:
Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com

Media Contact:
Jude Gorman / Kiki Torpey
Collected Strategies
PDS-CS@collectedstrategies.com

New report finds AI assistant adoption climbing across every age group, women continuing to lead usage on mobile, and early growth in ad monetization

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — Comscore, a global leader in measuring and analyzing consumer behaviors, today released its Q2 2026 AI Intelligence Report, which shows that consumers are rapidly diversifying which AI assistants they use even as the overall category keeps expanding.

According to Comscore panel data, Claude’s share of total AI prompt volume grew from 2% in January 2026 to 11% in June 2026, while Google’s Gemini nearly doubled, from 17% to 30%, over the same period. ChatGPT remains the clear category leader but has seen its share of AI prompt volume fall from 70% to 50% as the competitive field widened. The report also found that the rate of growth on mobile is now outpacing desktop, with adoption of AI assistant up 12% and 25% respectively since the start of 2025.

“As competition among AI assistants intensifies and prompt volume shifts across platforms, brands and publishers can no longer assume that a single AI experience defines the market,” said Smriti Sharma, Chief Analytics and Technology Officer at Comscore. “Understanding where consumers are turning with their questions, which sources AI cites in response, and how those interactions convert into measurable business outcomes is becoming essential to any brand’s growth strategy in this new era of AI-influenced discovery.”

The report offers an independent, comprehensive, panel-based view of how AI usage, AI-powered search, and brand visibility inside AI responses are evolving together. As prompt volume fragments across a growing set of platforms and AI overviews become a fixture of everyday search, the data offers marketers, publishers, and platforms a clearer picture of where consumer attention is migrating.

Comscore Q2 2026 AI Intelligence Report Key Findings

• ChatGPT remains the category leader, but its share is eroding. ChatGPT reached 168 million desktop conversations in June 2026 and grew its multiplatform visitation to 99 million from 59 million a year earlier, yet its share of total AI prompt volume fell from 70% to 50% between January and June 2026 as consumers spread their usage across a wider range of tools.

• Claude’s share increased more than fivefold during time. Claude’s share of the AI prompt volume rose from 2% to 11% between January and June 2026. Desktop conversations increased from 1.1 million in October 2025 to a high of nearly 40 million in April 2026 before plateauing at 22.3 million in June — still about 20 times the levels in October 2025, even as growth slowed through the summer months.

• Gemini’s share of AI prompt volume increased from 17% to 30% from January to June 2026, with desktop conversations rising from 8 million to 89 million over the past year despite a similar early-summer slowdown.

• AI assistant reach continues to expand. In June 2026, 35% of desktop users and 29% of mobile users visited an AI assistant, compared to 25% and 12%, respectively, in January 2025.

• Women are still the biggest users of AI assistants on mobile. Female mobile index scores for ChatGPT, Copilot and Gemini (110, 119 and 115 respectively) continued to outperform male usage on mobile in June 2026 despite men over-indexing on desktop on the same platforms.

• Major social platforms have experienced significant uplift in visitors using AI assistants between June 2025 and June 2026. TikTok grew from 32% to 53%, Meta from 32% to 47% and YouTube from 30% to 39%.

• AI overviews continue to grow their presence in search. Google desktop searches with an AI overview grew from 25.8% in July 2025 to 39.4% in Jun 2026, and Bing’s Copilot Search increased from 11.8% to 17.3% in the same time period.

• AI is emerging as both a brand discovery and monetization channel. Fashion brand mentions in AI responses grew 123% and Health/Beauty brand mentions grew 150% between January and March 2026, while sponsored ads began appearing inside AI travel search results — rising from 6% of hotel-related prompts with source links in March 2026 to 24% by May 2026.

The full Q2 2026 AI Intelligence Report is available for download here.

About Comscore
Comscore is a global, trusted partner for planning, transacting, and evaluating media across platforms. With an unmatched data footprint that combines digital, linear TV and over-the-top viewership intelligence with advanced audience insights, Comscore empowers media buyers and sellers to quantify their multiscreen behavior and make meaningful business decisions with confidence. A proven leader in measuring digital and TV audiences and advertising at scale, Comscore is the industry’s emerging third-party source for reliable and comprehensive cross-platform measurement.

Media
Marie Scoutas
Comscore, Inc.
press@comscore.com

• Supported by Schneider Electric’s SE Advisory Services, the FRC Will Help Provide Fashion Industry Suppliers with Resources to Adopt Renewable Electricity 

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — Levi Strauss & Co. and  Marks & Spencer (M&S), in partnership with SE Advisory Services, Schneider Electric’s global consulting practice, today launched the Fashion Renewable Collaborative (“FRC”) and are inviting fashion brands across the industry to join the effort. Announced at New York Climate Week, the FRC is designed to help interested suppliers adopt renewable electricity at scale through coordinated brand engagement and practical implementation support. By modeling a shared approach to supplier engagement, the collaborative aims to facilitate renewable electricity adoption across global fashion supply chains and help manufacturers understand, access and implement renewable electricity solutions at scale. 

The launch comes as fashion brands seek new ways to translate their individual climate commitments into measurable, durable emissions reductions across complex global supply chains. While many companies have established ambitious climate goals, supplier adoption of renewable electricity remains a critical challenge due to market barriers, limited resources, fragmented engagement efforts, and differing requests from multiple customers. The opportunity is significant: textile processing, the fabric mills and dye houses at the heart of global fashion supply chains, accounts for more than half of the apparel industry’s emissions, according to the  Apparel Impact Institute, making supplier adoption of renewable electricity one of the fastest and most scalable paths to progress. 

The FRC was established to address this challenge through a comprehensive framework that can reduce the burden on interested suppliers while accelerating impact across the fashion industry. According to the Roadmap to Net Zero from the World Resources Institute and the Apparel Impact Institute, shifting manufacturing to renewable electricity is the single largest decarbonization lever, representing roughly two-thirds of the sector’s identified emissions-reduction potential. 

Katharine Beacham, Head of Sustainability and Materials in Fashion, Home & Beauty at M&S, said: “At M&S, we know that real change happens when we collaborate. Through our sustainability programme, Plan A, we’re committed to becoming a net zero business across our value chain by 2040, and that means working with others to make the transition to renewable electricity easier for our supply partners. Building on the work already underway through Re:Spark, our supply chain decarbonisation programme, the Fashion Renewable Collaborative will provide practical support, resources and greater access to renewable electricity, helping suppliers take action and facilitating change in the fashion supply chain.” 

The FRC is one of the first fashion industry initiatives focused on providing real renewable electricity solutions. Unlike programs primarily focused on commitments or a roadmap, the FRC gives suppliers the opportunity to access the tools, knowledge and support to accelerate their energy transition. This includes digital education, powered by  Resource Advisor+, SE Advisory Services AI-native energy and sustainability intelligence platform, market guidance, and significant support in assessing and procuring renewable electricity.  

The FRC is built around a structured implementation model that helps suppliers first learn and then execute through digital education modules. Participating brands benefit from a common approach, while suppliers gain access to support designed to reduce complexity and improve access to credible renewable electricity solutions, including power purchase agreements (PPAs), energy attribute certificates (EACs), on-site and distributed renewable generation, energy storage, and other proven procurement and deployment pathways.  

The Potential of Coordinated Support

At New York Climate Week and beyond, the Fashion Renewable Collaborative is inviting additional fashion brands to join as sponsors and members to broaden the reach and impact of renewable electricity education, resources, and support among participating suppliers. 

“It’s become abundantly clear that the most effective way forward on emissions reduction is working in partnership with suppliers,” said Jennifer DuBuisson, Senior Director, Sustainability, Levi Strauss & Co. “Initiatives like this create better working relationships and a more effective path forward. The Fashion Renewable Collaborative enables greater support of suppliers that want to access or would like to increase use of renewable electricity but haven’t been able to so far, helping facilitate adoption while reducing unnecessary duplication. It’s a natural extension of work we’ve already been doing with our own suppliers, and we’re glad to bring that experience into this effort with M&S and SE Advisory Services.”  

The FRC initiative builds on successful engagement efforts already underway. Together, the two programs registered nearly 500 supplier facilities, demonstrating growing interest among suppliers seeking practical pathways to decarbonization.  

The FRC is supported by SE Advisory Services, which will serve as the program’s global implementation partner. Schneider Electric brings extensive experience in designing and managing large-scale supply chain decarbonization programs, including more than 20 active initiatives globally involving over 3,100 supplier companies and 16 multi-buyer renewable energy cohorts. As a global energy technology leader, Schneider Electric combines deep energy markets expertise, digital platforms, and on-the-ground implementation support to help suppliers move from commitment to execution. 

“Many fashion brands have made their individual commitments. Now the focus must be on helping suppliers deliver against them,” said Steve Wilhite, Executive Vice President, SE Advisory Services. “The Fashion Renewable Collaborative is designed to provide suppliers with practical support and engagement that can help accelerate renewable electricity adoption at scale. We’re excited to support Levi Strauss & Co. and M&S, and future participating brands as they work together to drive meaningful supply chain decarbonization.” 

The FRC will leverage SE Advisory Services’  Resource Advisor+ for Supply Chain product to support supplier onboarding, engagement tracking, readiness assessments, and progress monitoring. Together, these capabilities help create a consistent, digitally scalable experience for both brands and suppliers.  

By participating, brands can directly support suppliers’ ability and desire to adopt renewable electricity while reducing supplier fatigue, expand renewable electricity access, and helping brands achieve their individual supply chain decarbonization goals. 

For more information about the Fashion Renewable Collaborative, visit Resource Advisor+ for Supply Chain.  

Press contact: mediarelations@se.com

About Marks & Spencer 

Marks & Spencer (“M&S”) is a leading British retailer with a strong presence across the UK and in 32 international markets. M&S serves 32 million customers every year with exceptional quality products at value they can trust. Behind M&S is over 63,000 colleagues who bring passion and expertise to everything they do.   

For more than 140 years, M&S has built trust by doing the right thing by its colleagues, customers and the communities. Underpinning this commitment is Plan A – M&S’ sustainability programme – a promise to always source and make products with care. Plan A is also an integral enabler of M&S’ strategy to reshape for sustainable, profitable growth and to become a net zero business across its value chain by 2040.  

About Levi Strauss & Co. 

Levi Strauss & Co. (LS&Co.) is one of the world’s largest brand-name apparel companies and a global leader in jeanswear. The company designs and markets jeans, casual wear and related accessories for men, women and children under the Levi’s®, Levi Strauss Signature™, and Beyond Yoga® brands. Its products are sold in approximately 120 countries worldwide through a combination of chain retailers, department stores, online sites, and a global footprint of approximately 3,300 retail stores and shop-in-shops. Levi Strauss & Co.’s reported 2025 net revenues were $6.3 billion. For more information, go to http://levistrauss.com , and for financial news and announcements go to http://investors.levistrauss.com . 

About Schneider Electric

Schneider Electric is a global energy technology leader, driving efficiency and sustainability by electrifying, automating, and digitalizing industries, businesses, and homes. Its technologies enable buildings, data centers, factories, infrastructure, and grids to operate as open, interconnected ecosystems, enhancing performance, resilience, and sustainability. The portfolio includes intelligent devices, software-defined architectures, AI-powered systems, digital services, and expert advisory. With 160,000 employees and 1 million partners in over 100 countries, Schneider Electric is consistently ranked among the world’s most sustainable companies. 

www.se.com

Learn more about Advancing Energy Tech on Schneider Electric Insights.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/35b959aa-f3e3-4f81-9c27-5aab54da9add

New operation expands TTEC’s automotive CX capabilities in Egypt as part of a seven-year strategic collaboration with Volkswagen Group UK Ltd.

AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) — TTEC, a leading global consulting, technology, and managed services company delivering solutions at the intersection of data, AI, and customer experience (CX), today announced the launch of a new customer experience operation in Cairo supporting Volkswagen Group UK Ltd. (VWG).

The new operation expands TTEC’s automotive CX capabilities in Egypt and supports VWG’s customer care operations across digital and voice channels. The program will leverage TTEC’s multilingual workforce, automotive expertise, and AI-enabled CX capabilities to help deliver connected and consistent experiences for VWG customers.

“Providing a seamless customer experience is integral to how we support our customers and our brands,” said Chris Stevens, Volkswagen Group UK Head of Customer Management. “The launch of this operation in Cairo with TTEC gives us access to skilled talent and capabilities that will help us deliver consistent, high-quality support as our customer needs continue to evolve.”

The Cairo launch is part of a new seven-year strategic collaboration between TTEC and VWG, announced earlier this year. The agreement expands TTEC’s role in supporting VWG’s customer experience operations and includes customer care, case management, connected vehicle support, and digital engagement.

The development complements Volkswagen Group UK’s broader CX strategy, with teams positioned across multiple locations to best support the Group’s customers. The Cairo operation adds to that network while bringing TTEC’s multilingual CX expertise and automotive experience to the Group’s customer operations.

TTEC entered Egypt in 2023 and has continued to expand its presence, including the opening of a state-of-the-art facility in Maadi Technology Park. TTEC Egypt supports multilingual customer experience, technical support, AI-enabled services and back-office operations for global clients. TTEC currently supports 11 languages in Egypt, including Arabic, English, French, German, Italian and Spanish.

“Cairo has quickly become a key hub for multilingual global CX, and we’re excited to continue our longstanding relationship with Volkswagen Group UK in Egypt,” said John Abou, CEO, TTEC Engage. “TTEC brings together a highly skilled workforce, AI-enabled technology and decades of automotive expertise to create a customer experience that differentiates the ownership experience across Volkswagen brands.”

The launch further strengthens TTEC’s position as a CX partner for the automotive industry and expands its ability to support automotive customers across the customer lifecycle. It also reflects TTEC’s continued investment in Egypt as a strategic delivery hub connecting Europe, the Middle East, and Africa. In 2025, TTEC announced plans to expand its Egyptian workforce by an additional 3,500 employees by 2029 to meet growing global demand for multilingual CX and digital services.

About TTEC

TTEC Holdings, Inc. (NASDAQ: TTEC) is a leading global consulting, technology, and managed services company delivering solutions at the intersection of data, AI, and customer experience. Serving iconic and disruptive brands, TTEC’s outcome-based solutions span the entire enterprise, touch every virtual interaction channel, and improve each step of the customer journey. Leveraging next-generation digital technology, the Company’s TTEC Digital business designs, builds, and operates omnichannel contact center technology, CRM, AI, and analytics solutions. The Company also delivers AI-enhanced customer engagement, customer acquisition and growth, tech support, back-office, and fraud prevention services. Founded in 1982, TTEC’s singular obsession with CX excellence has earned it leading client, customer, and employee satisfaction scores across the globe. The Company’s employees operate on six continents and bring technology and humanity together to deliver happy customers and differentiated business results. To learn more, visit ttec.com.

Media Contact
Meredith Matthews
meredith.matthews@ttec.com 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dbd050a7-e7e3-4d50-8ce7-b84a63938298

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — newcleo plc (“newcleo” or the “Company”), a pioneer in advanced modular reactor (“AMR”) technology and nuclear fuel manufacturing, announced that its ordinary shares and warrants will begin trading on the Nasdaq Global Select Market today, September 22, 2026, under the ticker symbols “NWCL” and “NWCLW”, respectively.

“Today marks a pivotal milestone for newcleo as we bring our technology to the public markets,” said Stefano Buono, CEO and co-founder of newcleo. “As a Nasdaq-listed company, we have the capital and the platform to accelerate deployment of our reactor and fuel manufacturing technology across Europe and the United States, and to advance our mission of closing the nuclear fuel cycle. We could not be more excited to kick off this next chapter of our company’s history.”

newcleo’s Nasdaq listing will support its global growth, completing and operating its 10MWth non-nuclear demonstrator in Italy, advancing regulatory and licensing interactions with U.S. and French nuclear safety regulators, and to continue pursuing commercial opportunities to deploy its reactors and fuel manufacturing facilities in the U.S. and Europe.

About newcleo

newcleo is an innovative nuclear technology company developing advanced modular reactors and nuclear fuel designed to deliver clean, safe and sustainable energy at competitive costs. newcleo’s technology combines lead-cooled fast reactors with fuel manufactured from recycled nuclear materials, with the aim of providing abundant and reliable electricity and heat to industrial users while enabling the closure of the nuclear fuel cycle. newcleo brings together more than 900 highly skilled employees across Europe and the United States, spanning reactor and fuel design, engineering, and manufacturing. Through a vertically integrated supply chain and a growing network of strategic partnerships, newcleo is working to turn proven scientific and engineering solutions into deployable nuclear energy assets. For more information visit www.newcleo.com.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the U.S. federal securities laws. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding the completed business combination between NewHold Investment Corp III and newcleo; the anticipated benefits of the transaction; expected trading of the combined company’s securities on Nasdaq; the completion of investments from certain institutional investors; the expected amount of gross proceeds from any investments or other financing arrangements; the anticipated use of proceeds from such investments or financing arrangements; newcleo’s development and commercialization of its lead-cooled fast reactor technology, mixed-oxide fuel capabilities and related products and services; the expected timing, cost, performance and benefits of newcleo’s demonstration projects, fuel facilities, reactor deployments and licensing activities; newcleo’s ability to execute its business strategy, develop its technology, obtain required regulatory approvals, permits and licenses, enter into commercial arrangements, achieve its market opportunity and positioning and support the growth of advanced nuclear energy; newcleo’s expectations regarding strategic partnerships, customer demand, project pipeline, revenue streams, capital expenditures and financing needs; and other statements regarding management’s intentions, beliefs, or expectations with respect to newcleo’s future performance, are forward-looking statements. Forward-looking statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “develop,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on newcleo’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. You should carefully consider the foregoing factors and the other risks and uncertainties described in other documents filed from time to time by newcleo with the U.S. Securities and Exchange Commission. Additional risks and uncertainties not currently known or that are currently deemed immaterial may also cause actual results to differ materially from those expressed or implied by such forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and newcleo does not assume any obligation or intend to update or revise these forward-looking statements, each of which is made only as of the date of this press release.

For enquiries

Investor contact
newcleo@icrinc.com

Media contact
newcleo press office: media@newcleo.com
U.S. media inquiries: newcleo@icrinc.com

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend the corporate presentation at https://lythampartners.com/fall2026/

CUPERTINO, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced today that Laxminarayan Bhat, PhD., Founder, President and CEO, will present will participate in a webcast presentation at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

DATE: September 29^th
TIME: 12:30 PM ET

Company Webcast

The webcast presentation will take place at 12:30 PM ET on Tuesday, September 29, 2026. The webcast can be accessed by visiting the conference website at https://lythampartners.com/fall2026/ or directly at https://app.webinar.net/vNl8PQxLKqg. The webcast will also be available for replay following the event.

1×1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at rvph@lythampartners.com or register for the event at https://lythampartners.com/fall2026invreg/.

About Reviva

Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Company’s plans for its brilaroxazine program including intended steps of advancing clinical development and regulatory strategy towards potential approval, statements about the Company’s planned registrational RECOVER-2 Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia, statements about the Company’s planned use of a new form of brilaroxazine in its RECOVER-2 Phase 3 trial and in its future NDA submission, statements about anticipated FDA feedback, and the projected timing of the foregoing, statements about the Company’s planned bioequivalence study, statements about the expected timing of initiation of patient enrollment in the RECOVER-2 Phase 3 trial, statements about the Company’s strategy to strengthen the long-term value of brilaroxazine and the potential to extend patent protection and commercial exclusivity, including the expected duration thereof, statements about potential future NDA and other future regulatory submissions, statements about the Company’s expectations regarding the anticipated clinical profile of its product candidates, including statements regarding anticipated efficacy or safety profile, and those relating to the Company’s expectations, intentions or beliefs regarding matters including product development and clinical trial plans and the timing thereof, including the anticipated timing of the availability of trial data, clinical and regulatory timelines and expenses, planned or intended additional trials or studies and the timing thereof, planned or intended regulatory submissions and the timing thereof, or trial data or results or the implications thereof generally, statements about the quotation of the Company’s common stock on the OTCQB Venture Market (which is subject to additional risks compared to being listed on a national securities exchange including the Company’s ability to maintain compliance with the standards for continued quotation on the OTC Markets, together with limited liquidity, increased volatility, sporadic trading in the public market for the Company’s common stock, and that the Company’s ability to raise additional capital while trading on the OTC Markets may be adversely impacted), statements about market opportunity, ability to raise sufficient funding, the Company’s cash position and its projected cash runway, statements about competitive position, possible or assumed future results of operations, business strategies, potential opportunities for development including partnerships, growth or expansion opportunities, and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2025, the Company’s Quarterly Reports on Form 10-Q filed since such Annual Report on Form 10-K, and the Company’s other filings from time to time with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com

About Lytham Partners
Lytham designs one of the most effective platforms for public companies to communicate corporate information to the largest and most appropriate cross section of institutional investors. Combining Corporate Positioning, Corporate Access & Consulting Services, our platform offers a level of shareholder value that remains competitive in the industry. 

Lytham Partners
Ben Shamsian CPA

Vice President, Investor Relations
Lytham Partners, LLC
shamsian@lythampartners.com

Expands programmatic access to 800,000 verified prescribers directly in the EHR workflow, making OptimizeRx’s point of care inventory directly available to advertisers using The Trade Desk

WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) — OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, today announced an integration with OpenPath, The Trade Desk’s supply path optimization solution, making OptimizeRx’s authenticated point of care inventory available directly to advertisers using The Trade Desk’s leading, data-driven demand side platform (DSP).

Through OpenPath, advertisers using The Trade Desk will gain direct access to OptimizeRx’s proprietary network of more than 400 electronic health record (EHR) and e-prescribe systems, reaching 800,000 verified HCPs. The integration expands the differentiated healthcare inventory available to life sciences advertisers on The Trade Desk, enabling them to incorporate OptimizeRx’s point of care inventory into their broader programmatic media strategies.

Bringing Point of Care into Mainstream Programmatic Buying Through OpenPath

Historically, EHR advertising inventory has been primarily purchased through direct, managed-service relationships or specialized healthcare platforms, which has made it challenging to incorporate into many brands’ omnichannel marketing strategies. By integrating with OpenPath, OptimizeRx can make its point of care inventory directly available to advertisers using The Trade Desk, providing another way for life sciences marketers to incorporate HCP media into their broader programmatic strategies.

OpenPath provides advertisers with a direct connection to premium publisher inventory, helping improve transparency and efficiency across the advertising supply chain. OptimizeRx’s integration extends that direct access to its EHR point of care network alongside the broader range of digital media advertisers can buy through The Trade Desk. As a result, advertisers can incorporate in-workflow placements into a buying infrastructure already central to their broader media strategy.

“Point of care has matured beyond a specialty media buy, and the next step is integrating it into the way all HCP media is planned and bought,” said Stephen Silvestro, CEO, OptimizeRx. “By integrating with OpenPath, we can make our authenticated clinical inventory directly accessible to a broader base of advertisers using The Trade Desk, without losing what makes that inventory distinct: verified providers, real clinical workflows, and proximity to the treatment decision.”

“Life sciences advertisers increasingly want greater choice and direct access to the differentiated inventory that matters to their campaigns,” said Baron Harper, VP, Business Development, The Trade Desk. “By connecting OptimizeRx’s point of care network to OpenPath, advertisers can access authenticated HCP inventory directly through The Trade Desk and incorporate it alongside their broader media investments. This gives advertisers more flexibility in how they reach healthcare professionals while bringing another differentiated source of supply to the open internet.”

Building a Broader Programmatic Distribution Network for Point of Care

The OpenPath integration is the latest step in OptimizeRx’s broader programmatic distribution strategy for its proprietary EHR network. By creating multiple buyer entry points, OptimizeRx can reach new sources of advertiser demand, give life sciences marketers greater flexibility in how they access the network, and make EHR inventory more broadly available across the programmatic HCP ecosystem.

Availability

OptimizeRx’s EHR point of care inventory is expected to be available to advertisers using The Trade Desk through OpenPath in the fourth quarter of 2026.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood® Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “brings”, “expands”, “will”, “can”, “enabling”, “integrating”, “helping”, “improve” or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the availability of OptimizeRx’s EHR inventory on the Trade Desk through OpenPath, advertisers’ ability to directly connect to premium publisher inventory which will help improve transparency and efficiency across advertising supply chains, marketers’ ability to incorporate in-workflow placements into their current buying infrastructure, the Company’s ability to make its authenticated clinical inventory directly accessible to a broader base of advertisers without losing what makes the inventory distinct, the Company’s ability to provide advertisers direct access to differentiated inventory that matters to their campaigns, and the Company’s ability to reach new sources of advertiser demand and make EHR inventory more broadly available across the programmatic HCP ecosystem. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions regarding the Company’s business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with eRx platforms and EHR networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. 

OptimizeRx Contact 
Jennifer Dinkel, SVP Marketing 
jdinkel@optimizerx.com 

Investor Relations Contact 
Douglas Farrell 
LifeSci Advisors, LLC 
dfarrell@lifesciadvisors.com 

Press Inquiries 
Matter Communications 
optimizerx@matternow.com 

Partnership Inquiries
Louis Trivento, SVP Strategic Partnerships 
ltrivento@optimizerx.com